GSA Capital Partners LLP Invests $753,000 in Ventyx Biosciences, Inc. $VTYX

GSA Capital Partners LLP bought a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 242,229 shares of the company’s stock, valued at approximately $753,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Affinity Asset Advisors LLC acquired a new stake in Ventyx Biosciences during the 2nd quarter worth about $9,707,000. Vanguard Group Inc. increased its position in shares of Ventyx Biosciences by 19.2% in the third quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock worth $11,725,000 after acquiring an additional 607,725 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Ventyx Biosciences during the second quarter valued at approximately $5,129,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Ventyx Biosciences by 8.4% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 945,206 shares of the company’s stock valued at $2,023,000 after acquiring an additional 73,601 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Ventyx Biosciences by 925.6% in the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock valued at $1,012,000 after acquiring an additional 794,401 shares in the last quarter. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Insider Buying and Selling

In other Ventyx Biosciences news, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the sale, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. The trade was a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John Nuss sold 12,675 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at approximately $3,778,793.32. This trade represents a 2.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 14.49% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on VTYX shares. Wells Fargo & Company reiterated an “equal weight” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a research report on Thursday, January 8th. HC Wainwright cut Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 target price for the company. in a research report on Thursday, January 8th. UBS Group reiterated a “neutral” rating and set a $14.00 price target (down previously from $20.00) on shares of Ventyx Biosciences in a report on Thursday, January 8th. Piper Sandler downgraded Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective for the company. in a research note on Thursday, January 8th. Finally, Lifesci Capital restated a “market perform” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Eight investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Ventyx Biosciences presently has a consensus rating of “Reduce” and an average target price of $14.00.

Ventyx Biosciences Price Performance

VTYX opened at $13.97 on Friday. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $25.00. The business has a 50-day moving average of $12.17 and a 200-day moving average of $7.66. The company has a market capitalization of $1.00 billion, a PE ratio of -9.31 and a beta of 1.25.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.